A Pharmacokinetic Interaction Study of Sorafenib and Iced Teas in Rats Using UPLC-MS/MS: An Illustration of Beverage-Drug Interaction.
Animals
Beverages
/ analysis
Carcinoma, Hepatocellular
/ drug therapy
Chromatography, Liquid
/ methods
Cytochrome P-450 CYP3A
/ pharmacokinetics
Disease Models, Animal
Drug Interactions
Erlotinib Hydrochloride
/ blood
Liver Neoplasms
Male
Plant Exudates
/ pharmacokinetics
Rats
Rats, Wistar
Sorafenib
/ administration & dosage
Tandem Mass Spectrometry
/ methods
Tea
/ chemistry
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2019
2019
Historique:
received:
25
05
2019
revised:
01
09
2019
accepted:
22
10
2019
entrez:
25
12
2019
pubmed:
25
12
2019
medline:
12
5
2020
Statut:
epublish
Résumé
Iced teas (ITs), also known as ready-to-drink teas, have gained much popularity among many nations. The modulatory effect of tea beverages on CYP3A4 increases the possibility of their potential interactions with many coadministered medications. Being a substrate of CYP3A4, sorafenib (SOR), the first-line therapy for the treatment of hepatocellular carcinoma, shows a great probability to exhibit pharmacokinetic (PK) interaction with ITs. For this purpose, different groups of Wistar rats were given oral doses of SOR (40 mg/kg), along with different types of ITs. The concentration of SOR in rat plasma was determined using UPLC-MS/MS. Chromatographic analysis was performed on a C18 analytical column, Acquity UPLC BEH™ (100 × 1.0 mm, i.d., 1.7
Identifiants
pubmed: 31871933
doi: 10.1155/2019/2410845
pmc: PMC6907072
doi:
Substances chimiques
Plant Exudates
0
Tea
0
Sorafenib
9ZOQ3TZI87
Erlotinib Hydrochloride
DA87705X9K
Cytochrome P-450 CYP3A
EC 1.14.14.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2410845Informations de copyright
Copyright © 2019 Hadir M. Maher et al.
Déclaration de conflit d'intérêts
The authors declare no conflicts of interest.
Références
Food Chem Toxicol. 2012 Dec;50(12):4375-81
pubmed: 22960141
Bioanalysis. 2018 Jul;10(14):1099-1113
pubmed: 30047806
Food Chem Toxicol. 2014 Aug;70:120-7
pubmed: 24815822
Invest New Drugs. 2011 Dec;29(6):1511-4
pubmed: 20706860
Neuro Oncol. 2013 Apr;15(4):490-6
pubmed: 23328813
PLoS One. 2018 Jun 14;13(6):e0199208
pubmed: 29902246
Biol Pharm Bull. 2015;38(11):1788-93
pubmed: 26521829
Ther Drug Monit. 2017 Feb;39(1):43-54
pubmed: 27861317
Oncologist. 2017 May;22(5):505-e49
pubmed: 28341759
J Chromatogr B Analyt Technol Biomed Life Sci. 2019 Feb 15;1108:25-31
pubmed: 30660839
Oncol Lett. 2016 Aug;12(2):1223-1232
pubmed: 27446421
Drug Metab Pharmacokinet. 2013;28(6):514-8
pubmed: 23698259
PLoS One. 2016 Dec 19;11(12):e0167906
pubmed: 27992451
J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Nov 1;878(29):3033-8
pubmed: 20870468
Anticancer Drugs. 2009 Aug;20(7):584-8
pubmed: 19491656
Clin Pharmacokinet. 2014 Feb;53(2):185-96
pubmed: 24135988
Med Oncol. 2015 Jan;32(1):335
pubmed: 25429830
Lab Invest. 2011 Feb;91(2):241-51
pubmed: 20921950
Cancer Chemother Pharmacol. 2013 Jul;72(1):269-72
pubmed: 23673446
J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Apr 1;1049-1050:30-40
pubmed: 28260629
J Mol Med (Berl). 2011 Jun;89(6):595-602
pubmed: 21331509
J Pharm Biomed Anal. 2017 Apr 15;137:258-267
pubmed: 28167419
Gastroenterol Hepatol (N Y). 2015 Apr;11(4):253-5
pubmed: 27099597
Xenobiotica. 2016 Jul;46(7):651-658
pubmed: 26582036
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Aug 15;1028:100-110
pubmed: 27336702
J Pharm Biomed Anal. 2017 Aug 5;142:42-48
pubmed: 28494338
J Clin Oncol. 2011 Aug 20;29(24):3293-300
pubmed: 21768474
J Adv Res. 2017 May;8(3):289-295
pubmed: 28337346
J Pharm Biomed Anal. 2016 May 30;124:216-227
pubmed: 26966895
Cancer Biother Radiopharm. 2017 Jun;32(5):176-183
pubmed: 28622037
Food Chem Toxicol. 2011 Jun;49(6):1410-5
pubmed: 21440026
Eur J Cancer. 2012 Mar;48(4):465-74
pubmed: 22285181
Eur J Pharm Sci. 2016 Jun 30;89:137-45
pubmed: 27130545
Pharm Biol. 2017 Dec;55(1):1863-1867
pubmed: 28614959
Target Oncol. 2017 Apr;12(2):243-253
pubmed: 28299600